NIH Asks Permission to Keep Tracking Its Free Helpers
Published Date: 12/18/2025
Notice
Summary
The NIH is asking for a 30-day public comment on their request to keep collecting info from special volunteers and guest researchers. This affects people who work or volunteer in NIH research programs and won’t cost anyone extra money. They want to make sure their forms stay approved and easy to use, so the research keeps running smoothly.
Analyzed Economic Effects
2 provisions identified: 1 benefits, 1 costs, 0 mixed.
NIH keeps forms for volunteers/researchers
NIH is asking OMB to extend three forms (NIH Form 590, NIH Form 590-1, and NIH Form 590-2; OMB control number 0925-0177, current expiration March 31, 2026) and requests approval for 3 years. People who work or volunteer in NIH intramural research will still need to complete these forms; NIH estimates a total annual burden of 652 hours (2,300 Special Volunteer/Guest Researcher Assignment responses at 6 minutes each, 2,100 Special Volunteer Agreement responses at 5 minutes each, and 200 Guest Researcher Agreement responses at 5 minutes each). There are no monetary costs to respondents other than their time.
Extra 30‑day public comment window
NIH opened an additional 30-day public comment period on this information collection; comments are best assured of full effect if received within 30 days of the December 18, 2025 publication. The earlier 60-day notice (published September 25, 2025) received no public comments, and this notice gives the public another chance to comment.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16683, Proposed Collection; 60-Day Comment Request; Data Use Certification for the NIH National Institute on Drug Abuse Data Share Site
The purpose of this notice is to inform the public of the information collection requirement for the NIDA Data Share, the data use terms and conditions, and to request a progress report statement at the time of renewal. In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-16544, Government-Owned Inventions; Availability for Licensing
The inventions listed below are owned by an agency of the U.S. Government and are available for licensing to achieve expeditious commercialization of results of federally-funded research for the benefit of the public health.
2026-16440, NIH Owned Invention Available for License: Soluble Tissue Factor, a Novel Target, and Antibodies, for Diagnosis, Prevention and Treatment of Thrombosis and Related Conditions
Scientists at the National Cancer Institute (NCI) have discovered a novel therapeutic, diagnostic and prognostic target for thrombosis: Soluble Tissue Factor (sTF). NCI has generated first-in- class antibodies and platform selectively neutralizing pathological coagulation while preserving normal hemostasis. This platform technology can be used to prevent, diagnose and treat pathological thrombosis caused by a variety of clinical conditions-including cancer, sepsis, infectious diseases (e.g., COVID), autoimmune disorders, trauma, heart conditions and inflammatory conditions. It offers a much more sensitive and specific test of thrombosis than the current D-dimer test. It may be applicable to any clinical condition which induces necroptosis, pyroptosis and NETtosis, such as cancer, neurodegenerative disease, ischemia-reperfusion and acute injuries, traumatic injuries, bacterial and viral infections, cardiovascular conditions, and atherosclerosis, inflammatory, autoimmune conditions, and others.
2026-16071, Proposed Collection; 60-Day Comment Request: The Impact of Clinical Research Training and Medical Education at the Clinical Center on Physician Careers in Academia and Clinical Research (Clinical Center)
In compliance with the requirement of the Paperwork Reduction Act of 1995, for opportunity for public comment on proposed data collection projects, the Clinical Center, the National Institutes of Health (NIH) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-15565, Proposed Collection; 60-Day Comment Request, Data Use Certification for the NIH Brain Development Cohorts (NBDC) Data Hub, (National Institute on Drug Abuse)
In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval. The purpose of this revision is to update instructions for the Research Data Use Statement and the Progress Report, and to add new instructions for attesting to National Institute of Standards & Technology (NIST) security compliance, and for a Project Close-out at the time of project completion. Burden levels remain unchanged.
2026-14966, Government-Owned Inventions; Availability for Licensing
The National Institutes of Health is offering a new Ebola vaccine invention for companies to license and develop quickly. This vaccine targets the Bundibugyo virus and promises fast and lasting protection, helping stop outbreaks in Central Africa. Businesses interested in licensing should act soon to bring this life-saving tech to market and can contact NIH for details.
Previous / Next Documents
Previous: 2025-23249, Questions and Answers Regarding Mandatory Cosmetics Recalls: Draft Guidance for Industry; Availability
The FDA just dropped a draft guide to help cosmetic companies understand how mandatory recalls work and what to expect if their products need to be pulled from shelves. This guide answers common questions about the recall process, making it easier for businesses to stay safe and compliant. Companies should send their feedback by February 17, 2026, so the FDA can finalize the rules—keeping everyone on track and avoiding costly surprises.
Next: 2025-23252, Use of Real-World Evidence To Support Regulatory Decision-Making for Medical Devices; Guidance for Industry and Food and Drug Administration Staff; Availability
The FDA just released updated rules on how real-world data can help approve medical devices faster and smarter. This affects medical device makers and FDA staff by giving clearer, better ways to use everyday health info for decisions. The new guidance starts December 18, 2025, aiming to speed up approvals without extra costs.